GSK3βhigh/NFATc1high in Treatment of Pancreatic Cancer: Gut | July 2026

Introduction:

Pancreatic ductal adenocarcinoma (PDAC) remains one of the most treatment-resistant cancers, with rapid recurrence and poor survival despite surgery and chemotherapy. This study identifies a novel molecular subtype of PDAC driven by GSK3β–NFATc1 signaling, providing new opportunities for biomarker-guided precision therapy.

Why was this study needed?

• PDAC is highly heterogeneous, but clinically useful molecular subtypes remain limited.
• Resistance to platinum chemotherapy is a major therapeutic challenge.
• Biomarkers predicting recurrence and treatment response are lacking.
• GSK3β has been implicated in PDAC progression, but its clinical significance remains unclear.
• Personalized therapeutic strategies are urgently needed.

Results:

• A highly aggressive GSK3βhigh/NFATc1high subtype was identified, accounting for approximately 14% of resected PDAC and strongly associated with early recurrence and poor survival.
• GSK3β–NFATc1 signaling promoted homologous recombination DNA repair by inducing BRCA and other DNA repair genes, resulting in cisplatin resistance.
• Inhibition of the GSK3β–NFATc1 pathway impaired DNA repair and restored cisplatin sensitivity, identifying a promising therapeutic vulnerability in this aggressive PDAC subtype.

Clinical Impact:

This study introduces GSK3βhigh/NFATc1high as a clinically relevant molecular subtype that may help identify patients at high risk of recurrence after surgery. Molecular stratification and targeted inhibition of the GSK3β–NFATc1 axis could improve the effectiveness of platinum-based chemotherapy and advance precision medicine in PDAC.

Bottom Line:

The GSK3βhigh/NFATc1high subtype defines an aggressive, chemotherapy-resistant form of pancreatic cancer. Targeting the GSK3β–NFATc1 signaling pathway may overcome platinum resistance and pave the way for biomarker-guided personalized treatment in PDAC.